Abstract
Objective To compare the efficacy of methotrexate and actinomycin D as single agents in first-line chemotherapy for women with low-risk gestational trophoblastic neoplasia (LR-GTN). Methods A total of 131 women with LR-GTN were randomized to receive a weekly pulsed dose of 30 mg/m 2 of methotrexate intramuscularly (n = 81) or a pulsed intravenous bolus of 1.25 mg/m 2 of actinomycin D every 2 weeks (n = 50). An additional cycle was administered as consolidation treatment following normalization of the serum level of β-human chorionic gonadotropin (< 5 IU/L). Results Complete remission was achieved in 48.14% of patients in the methotrexate group and 90.00% in the actinomycin D group ( P < 0.001). The mean number of treatment cycles needed to achieve response was lower in the actinomycin D group (4.8 vs 6.8). The risk of treatment failure was 26.4 greater with methotrexate than with actinomycin D (95% confidence interval, 5.7–22.6; P < 0.001). Conclusion Actinomycin D may be a better option than methotrexate as a first-line chemotherapy agent for patients with LR-GTN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Gynecology and Obstetrics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
